Blood News and Research

RSS

Elevated blood levels of HDL can be harmful to women with type 1 diabetes: Study

Elevated blood levels of high-density lipoprotein or "good" cholesterol, typically thought to protect against heart disease, may do the opposite in women with type 1 diabetes, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association.

28 Jun 2010

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

A statewide Ohio program significantly reduced the monthly rate of inappropriately scheduled births before 39 weeks gestation, helping to avoid expensive neonatal intensive care unit admissions and decrease the risk of infant deaths, according to two studies by the Ohio Perinatal Quality Collaborative recently published in the American Journal of Obstetrics & Gynecology.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Using an experimental mouse model for malaria, an international group of scientists has discovered that adding antioxidant therapy to traditional antimalarial treatment may prevent long-lasting cognitive impairment in cerebral malaria. Their findings were published online June 24, 2010, in the journal PLoS Pathogens.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Better test to predict menopause on the horizon

With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.

28 Jun 2010

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

OraSure Technologies, Inc. announced today that its OraQuick Hepatitis C Rapid Antibody Test has been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States.

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

Pennsylvania reports drop in hospital infections, other patient care issues include CT scans

The Pennsylvania Department of Health found that 12.5 percent fewer patients contracted infections in the state's hospitals in 2009 than a year earlier, according to the Pittsburgh Post-Gazette. But the reports shows that there were 25,914 infections in 2009. "'Though the report seems to show we're making progress, 25,914 is still a very large number and shows we still have our work cut out for us in bringing that number down,' Stephen Ostroff, the state's acting physician general, said Thursday.

25 Jun 2010

FDA approves OraQuick HCV Rapid Antibody Test for HCV

The U.S. Food and Drug Administration today announced approval of the first rapid blood test for antibodies to the hepatitis C virus for individuals 15 years and older.

25 Jun 2010

ARS study finds link between vitamin D and cognitive function

At a time when consumer interest in health-enhancing foods is high, Agricultural Research Service (ARS)-funded scientists have contributed to a limited but growing body of evidence of a link between vitamin D and cognitive function.

25 Jun 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

St. Jude Medical's Therapy Cool Path Ablation Catheter receives Japanese MHLW approval

St. Jude Medical, Inc., a global medical device company, today announced Japanese Ministry of Health, Labour and Welfare approval and reimbursement approval of its Therapy Cool Path Ablation Catheter. This marks the company's first entry into the irrigated catheter ablation market in Japan.

25 Jun 2010

Blood News and Research

Elevated blood levels of HDL can be harmful to women with type 1 diabetes: Study

Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010

OPQC Scheduled Birth Initiative reduces unnecessary planned late pre-term, near-term deliveries in Ohio

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Better test to predict menopause on the horizon

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

Pennsylvania reports drop in hospital infections, other patient care issues include CT scans

FDA approves OraQuick HCV Rapid Antibody Test for HCV

ARS study finds link between vitamin D and cognitive function

Japan's MHLW grants full marketing authorization to REVLIMID

St. Jude Medical's Therapy Cool Path Ablation Catheter receives Japanese MHLW approval

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News